Mitos y tabús sobre dependencia a psicofármacos
Palabras clave:
Psicofármacos, dependencia, abstinencia, recaída.Resumen
El manejo de la terapia farmacológica siempre ha sido un reto para la psiquiatría; a
pesar de la amplia evidencia disponible que soporta la eficacia y seguridad de los
psicofármacos, existen factores sociales y culturales que a lo largo de la historia
han demostrado conducen a mala adherencia al tratamiento y por tanto al fracaso
terapéutico.
Se revisarán las indicaciones principales de tres grupos de psicofármacos:
benzodiacepinas, antidepresivos y antipsicóticos y se trataran de establecer
indicaciones para uso racional de estos medicamentos que pueden impactar en la
reducción de posibilidad de aparición de dependencia, así como estrategias para
identificar síntomas asociados a ella que permitan al profesional de la salud realizar
intervenciones oportunas.
Citas
Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry [Internet]. 2010;167(6):686–93.
Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom [Internet]. 2020;89(5):283–306.
Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev [Internet]. 2021;4(4):CD013495.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet [Internet]. 2003;361(9358):653–61.
Récalt AM, Cohen D. Withdrawal confounding in randomized controlled trials of antipsychotic, antidepressant, and stimulant drugs, 2000-2017. Psychother Psychosom [Internet]. 2019;88(2):105–13.
Guy A, Brown M, Lewis S, Horowitz M. The “patient voice”: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Ther Adv Psychopharmacol [Internet]. 2020;10:2045125320967183.
Marsden J, White M, Annand F, Burkinshaw P, Carville S, Eastwood B, et al. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. Lancet Psychiatry [Internet]. 2019;6(11):935–50.
Manthey L, Lohbeck M, Giltay EJ, van Veen T, Zitman FG, Penninx BWJH. Correlates of benzodiazepine dependence in the Netherlands Study of Depression and Anxiety: Correlates of benzodiazepine dependence. Addiction [Internet]. 2012;107(12):2173–82
Fava GA. May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Ther Adv Psychopharmacol [Internet]. 2020;10:2045125320970325.
Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol [Internet]. 1989;25(3):213–20.
Song J, Shen G, Greenfield LJ Jr, Tietz EI. Benzodiazepine withdrawal-induced glutamatergic plasticity involves up-regulation of GluR1-containing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in Hippocampal CA1 neurons. J Pharmacol Exp Ther [Internet]. 2007;322(2):569–81.
Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy J-M, et al. Neural bases for addictive properties of benzodiazepines. Nature [Internet]. 2010;463(7282):769–74.
Cohen D, Recalt A. Discontinuing psychotropic drugs from participants in randomized controlled trials: A systematic review. Psychother Psychosom [Internet]. 2019;88(2):96–104.
Wafford KA. GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol [Internet]. 2005;5(1):47–52.
Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. Prim Care Companion CNS Disord [Internet]. 2005 [citado 2022 Feb 19];7(Suppl 2: Editor Choice):17365.
Hengartner MP, Plöderl M. Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA. Ther Adv Psychopharmacol [Internet]. 2021;11:20451253211032052.
Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health [Internet]. 2016;106(4):686–8. Disponible en: http://dx.doi.org/10.2105/AJPH.2016.303061
Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med [Internet]. 2008;50(4):428–36.
Crowley R, Kirschner N, Dunn AS, Bornstein SS, Health and Public Policy Committee of the American College of Physicians, Abraham G, et al. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: An American College of Physicians position paper. Ann Intern Med [Internet]. 2017;166(10):733–6.
Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?: Pharmaceutical stimulant diversion and misuse. Addiction [Internet]. 2012;107(3):467–77.
UpToDate [Internet]. Uptodate.com. [Disponible en 2022 Feb 19].
Kan CC, Hilberink SR, Breteler MHM. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach.ComprPsychiatry[Internet].2004;45(2):88–94.
Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev [Internet]. 2009;2(2):157–76.
National Survey of Drug Use and Health (NSDUH) releases [Internet]. Samhsa.gov. [citado 2022 Feb 19]
Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Libr [Internet]. 2018;2018(3). Disponible en: http://dx.doi.org/10.1002/14651858.cd011481.pub2
Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse, or dependence. Cochrane Database Syst Rev [Internet].2015;5:CD009652. Disponible en: http://dx.doi.org/10.1002/14651858.CD009652.pub227. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011.Pharmacopsychiatry [Internet]. 2011;44(6):195–235.
de Gier NAH, Gorgels WJMJ, Lucassen PLBJ, Oude Voshaar R, Mulder J, Zitman F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract [Internet]. 2011;28(3):253–9.
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet [Internet]. 1997;32(Supplement 1):1–21.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet [Internet]. 2013;382(9896):951–62.
Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol [Internet]. 2020;10:2045125320980573. Disponible en: http://dx.doi.org/10.1177/2045125320980573
Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend [Internet]. 2007;90(2–3):280–7.
Bschor T, Bonnet U, Pitzer M, Baethge C, Lieb K, Gertz H-J, et al. Stopping antidepressants: withdrawal symptoms and rebound effects : Review and practical recommendations: Übersicht und praktische Empfehlungen. Nervenarzt [Internet]. 2022;93(1):93–101.
Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Ther Adv Psychopharmacol [Internet]. 2021;11:2045125321991274.
Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol [Internet]. 2009;8(2):151–7.
Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial: The EMPOWER cluster randomized trial. JAMA Intern Med [Internet]. 2014;174(6):890–8. Disponible en: http://dx.doi.org/10.1001/jamainternmed.2014.949
Groot PC, van Os J. How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication. Ther Adv Psychopharmacol [Internet]. 2020;10:2045125320932452.
Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors: SSRi and dependence. Addiction [Internet]. 2012;107(5):900–8.
Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav [Internet]. 2019;97:111–21.
Stockmann T, Odegbaro D, Timimi S, Moncrieff J. SSRI and SNRI withdrawal symptoms reported on an internet forum. Int J Risk Saf Med [Internet]. 2018;29(3–4):175–80.
White E, Read J, Julo S. The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services? Ther Adv Psychopharmacol [Internet]. 2021;11:2045125320981174.
McCabe J, Wilcock M, Atkinson K, Laugharne R, Shankar R. General practitioners’ and psychiatrists’ attitudes towards antidepressant withdrawal. BJPsych Open [Internet]. 2020;6(4):64.
Read J. How common and severe are six withdrawal effects from, and addiction to, antidepressants? The experiences of a large international sample of patients. Addict Behav [Internet]. 2020;102(106157):106157.
Colzato L, Zhang W, Walter H, Beste C, Stock A-K. An oppositional tolerance account for potential cognitive deficits caused by the discontinuation of antidepressant drugs. Pharmacopsychiatry [Internet]. 2021;54(6):252–60.
Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AIM, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev [Internet]. 2013;(3):CD007726.
Kendrick T, Geraghty AWA, Bowers H, Stuart B, Leydon G, May C, et al. REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial. Trials [Internet]. 2020;21(1):419.
Baldessarini RJ, Tondo L. Effects of treatment discontinuation in clinical psychopharmacology. Psychother Psychosom [Internet]. 2019;88(2):65–70. Disponible en: http://dx.doi.org/10.1159/000497334
Domínguez V, Collares M, Ormaechea G, Tamosiunas G. Uso racional de benzodiacepinas: hacia una mejor prescripción. INNOTEC [Internet]. 2016 [citado el 29 de marzo de 2022];1(3):14–24.
Gómez San Luis AH, Almanza Avendaño AM. Benzodiacepinas: narrativas de adicción y recuperación de una anestesióloga. Health and Addictions/Salud y Drogas [Internet]. 2017;17(1):133–44.
C Ashton. Las Benzodiacepinas: Cuál es su mecanismo de acción y cómo suspender la ingestión (El Manual Ashton) [Internet]. Ed. revisada en agosto de 2002: benzo.org.uk [citado el 30 de marzo de 2022]. Disponible en: https://www.benzo.org.uk/espman/bzcha01.htm Gómez-Restrepo C, de Santacruz C, Rodriguez MN, Rodriguez V, Tamayo Martínez N, Matallana D, et al. Colombia 2015 National Mental Health Survey. Study protocol. Rev Colomb Psiquiatr [Internet]. 2016 [citado el 30 de marzo de 2022];45 Suppl 1:2–8.
Curry SH. Pharmacokinetics Of Antipsychotic Drugs. En: Antipsychotic Drugs and their Side-Effects. Elsevier; 1993. p. 127–44. 53. Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical pharmacokinetics of atypical antipsychotics: An update. Clin Pharmacokinet [Internet]. 2018;57(12):1493–528.
Descargas
Publicado
Versiones
- 2025-11-14 (3)
- 2025-11-14 (2)
- 2022-05-05 (1)
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Scientific and Eduaction Medical Journal
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Atribución – No comercial – Compartir igual: Esta licencia permite a otros distribuir, remezclar, retocar, y crear a partir de tu obra de modo no comercial, siempre y cuando te den crédito y licencien sus nuevas creaciones bajo las mismas condiciones.
Attribution-NonCommercial-ShareAlike 4.0 International
